Daiichi-Ranbaxy row: Delhi HC restricts selling ‘SRL’ trademark

The Ranbaxy Screenplay.

Contributing to the @Daiichi- @Ranbaxy row, the Delhi High Court has injuncted the Japanese pharma giant, @Daiichi Sankyo from attaching, selling or alienating “SRL” and allied trademarks in order to create any third-party interests in furtherance of recovering the amount due from the former @Ranbaxy promoters, the popular Singhs, who are now lodged in the vicinity of Tihar for alleged misappropriation of funds of Religare Finvest Ltd.

The court has directed the maintenance of status quo, especially with respect to the equity shareholdings. Daiichi has been in queue since 2016 in order to settle the Rs 3,500 crore arbitration award from the Singapore Tribunal against the Singhs.

Content retrieved from: https://www.thehindubusinessline.com/companies/daiichi-ranbaxy-row-delhi-hc-restricts-selling-srl-trademark/article32029136.ece.